A three-dimensional (3D) bioprinting technology capable of eliminating cancer cells using the function of immune cells has been developed for the first time in the world.
Investigators in Israel and Italy have developed a model of the blood-brain barrier, studies of which may lead to prevention of meningitis in newborns.
Today, MatTek Life Sciences and AIM Biotech announced a strategic partnership through which the AIM Biotech portfolio will be available for sale through MatTek.
In a noteworthy case study published in the Journal of Alzheimer's Disease investigators report autopsy findings in a 65-year-old woman with Alzheimer's disease (AD) who received three open label infusions of the experimental anti-amyloid beta (Aβ) antibody drug lecanemab.